Introduction
High-dose myeloablative chemotherapy supported by autologous PBPC infusion is widely used in the treatment of malignancies [1] [2] [3] [4] [5] and results in greater disease-free survival and overall survival. This treatment strategy is, however, associated with an obligate period of neutropenia and thrombocytopenia with an associated risk of infection and haemorrhage.
Compared to ABMT and cord blood transplants, cytokine-mobilized PBPC transplants are associated with more rapid neutrophil and platelet engraftment following high-dose chemotherapy. [6] [7] [8] Haemopoietic cytokines used to mobilize PBPC include G-CSF, GM-CSF, SCF and TPO. [9] [10] [11] [12] [13] Megakaryocytic progenitor mobilization and platelet recovery post high-dose therapy are dependent on the cytokine used in the mobilization protocol, its dose and whether it is combined with chemotherapy. 14, 15 Platelet recovery is also dependent on CD34 þ and CD34 þ / CD41a þ cell dose delivered to the patient and the use of cytokines in the post transplant period. 10, 16, 17 G-CSF, a lineage-specific growth factor, stimulates the proliferation and differentiation of neutrophil precursors and functional activation of mature neutrophils. 18 Human recombinant G-CSF is a proficient mobilizer of CD34 þ stem cells in the cytokine-alone 13, 19, 20 and chemotherapy plus cytokine settings. 21, 22 G-CSF is the main cytokine currently used in clinical practice.
In G-CSF-mobilized patients, there is a clear association between the number of CD34 þ cells infused and shortand long-term haemopoietic recovery. 23 A significant reduction in time to short-(425 Â 10 9 per litre) and longterm (4100 Â 10 9 per litre) platelet engraftment has been shown in patients receiving a CD34 þ cell dose between 3 Â 10 6 10 and 5 Â 10 6 per kg. 24 Commitment of CD34 þ progenitors to the megakaryocytic lineage can be defined by the expression of lineagespecific glycoproteins (GPs) on their surface. Increased expression of CD41a (GP IIbIIIa) and CD41b (GP IIb) occurs earliest, followed by GPs IIIa and Ib. 25 Analysis of platelet GPs on CD34 þ cells has shown that megakaryocytic reconstitution and platelet recovery post G-CSFprimed PBPC transplantation correlate better with number of CD34 þ /CD41a þ cells infused than total number of CD34 þ cells. 17 In addition, a close correlation has been observed between the number of CD34 þ /CD41a þ cells and colony-forming unit megakaryocyte (CFU-MK). 17, 26 Pegfilgrastim (Neulasta) is a polyethylene glycol-filgrastim conjugate with a longer half-life than the parent molecule (filgrastim) and a sustained duration of action, allowing several daily injections of filgrastim to be replaced by a single injection of pegfilgrastim. 27, 28 The noninferiority of pegfilgrastim to filgrastim, as measured by the duration of severe neutropenia in breast cancer patients undergoing chemotherapy, has been established in two large, randomized, double-blind clinical trials. 29, 30 The mobilization of CD34 þ cells by pegfilgrastim (30-300 mg/ kg body weight) has been examined in healthy human volunteers 28 and non-small cell lung cancer patients with chemotherapy-induced neutropenia, 31 and using fixed doses of pegfilgrastim in solid tumour patients. 32 The purpose of this phase I/II dose-finding study was to assess the proficiency of megakaryocytic progenitor mobilization with fixed doses of pegfilgrastim in patients with solid tumours receiving cytokine alone.
Patients and methods

Patients
Between August 2002 and April 2004, 61 chemotherapy naive patients, with advanced malignancies, were recruited as part of a phase I/II open-label, six-centre, UK-based trial examining the kinetics and efficacy of PBPC (CD34 þ ) mobilization following randomization to fixed doses of pegfilgrastim (6, 12 and 18 mg) or filgrastim 10 mg/kg per day in a cytokine alone cycle prior to the administration of paclitaxel and carboplatin chemotherapy. Written consent was obtained from all trial participants.
Patients were between 18 and 65 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, a pathologically confirmed diagnosis of solid tumour suitable for treatment with intensified carboplatin and paclitaxel, and were previously untreated with chemotherapy or radiotherapy. They had a life expectancy X12 weeks, an ANC 42 Â 10 9 per litre and a platelet count of 4100 Â 10 9 per litre, a glomerular filtration rate X60 ml/min and serum bilirubin o2 Â the upper limit of normal. A subset of this population (n ¼ 31), selected in order of recruitment (that is, the first 31 patients), was studied to determine the kinetics of mobilization of megakaryocytic progenitors into the peripheral blood.
Peripheral blood mononuclear cells
On days 1-7, 9 and 12 of cycle 0, approximately 10 ml of blood anticoagulated with 400 IU preservative-free heparin was obtained. Mononuclear cells (MNCs) were isolated using research grade Ficoll-Paque Plus solution (d: 1.077 g/ cm 3 ; Pharmacia Biotech, Uppsala, Sweden) density centrifugation. MNCs were collected from the interface, washed twice in PBS solution (Sigma-Aldrich, Poole, Dorset, UK) and resuspended in 1 ml Isocove's Modified Dulbecco's Medium (IMDM, Invitrogen Life Technologies, Paisley, UK) supplemented with 10% FCS (PAA Laboratories, Yeovil, UK) and 50 mg/ml gentamicin (Invitrogen Life Technologies). MNCs enumeration and viability was assessed using the Trypan Blue (SigmaAldrich) exclusion technique. Colony-forming cell assays and megakaryocyte colony-forming assays were set up immediately using viable cells. The remaining MNCs were stored at À801C in IMDM containing FCS, gentamicin and 10% DMSO (Sigma-Aldrich) for later use.
Methylcellulose colony-forming assay Semisolid progenitor cell colony assays were performed using methylcellulose. Cells were cultured in IMDM containing 1% methylcellulose (Stem Cell Technologies, London, UK), 30% FCS, 1% BSA, 2 mM L-glutamine and 10 À4 M b-mercaptoethanol and supplemented with K36EG (IL-3 (50 ng/ml), IL-6 (20 ng/ml), erythropoietin (6 U/ml; R&D Systems, Abingdon, Oxon, UK), c-Kit-ligand (20 ng/ ml) and G-CSF (10 ng/ml; Amgen Inc., Thousand Oaks, CA, USA)). Viable MNCs were plated in 0.33 ml of the methycellulose solution at a density of 1.67 Â 10 4 to 1.67 Â 10 5 per well (depending on the anticipated level of mobilization) in triplicate wells of a 24-well plate (Triple Red, Oxfordshire, UK). The surrounding empty wells were filled with approximately 1 ml of sterile water to provide 495% humidity and the plates were incubated for 14 days at 37 1C, 5% CO 2 . Colonies were identified and quantified visually using an inverted light microscope (CKX31; Olympus, London, UK). The total numbers of colonies per millilitre of blood was calculated.
Megakaryocyte colony-forming assay Megakaryocyte colonies were cultured from MNCs using the collagen based Megacult-C kit (Stem Cell Technologies, Vancouver, Canada). The protocol was followed according to the manufacturer's instructions. Viable MNCs were plated in dual-chambered slides at a density of 2.5 Â 10 5 cells per well in 825 ml of medium containing 25 ml serumfree IMDM, 300 ml collagen solution and 500 ml Megacult-C medium.
The final concentration of medium components was as follows: collagen, 1.1 mg/ml; BSA, 1%; bovine pancreatic albumin, 10 mg/ml; human transferring (iron saturated), 200 mg/ml; L-glutamine, 2 mM; 2-mercaptoethanol, 10
rh-thrombopoietin, 50 ng/ml; rhIL-6, 10 ng/ml rh-IL-3, 10 ng/ml. The dual-chambered slides were placed in covered 100 ml Petri dishes, containing an open 35 mm Petri dish (both from Becton Dickinson, Oxford, UK) filled with sterile water to provide 495% humidity, and incubated at 37 1C, 5% CO 2 for 12 days. The slides were then fixed by immersion in a methanol/acetone (BDH, Poole, Dorset, UK) mix (1:3 ratio) for 20 min. The slides were stored dry, at 4 1C in the dark for no more than 4 weeks before immunohistochemical staining.
Immunohistochemical staining of megakaryocyte colonies CFU-MK were identified by IHC staining of the platelet/ megakaryocyte-specific GP IIb/IIIa complex (CD41a) using the Megacult-C kit (Stem Cell Technologies, UK). The protocol was followed as per the manufacturer's instructions.
Cultures on slides were incubated in 5% human serum for 20 min, to block non-specific Ab binding. The slides were then exposed for 30 min to the primary Ab (mouse anti-human GPIIb/IIIa). The signal was then amplified using a secondary biotin-conjugated goat anti-mouse IgG and avidin-alkaline phosphatase conjugate. Later, addition of a naphthol-based alkaline phosphate substrate solution for 15 min produced a pink precipitate, the amount of which was proportional to the cell surface CD41a Ag. Slides were counterstained Evan's blue. As a result, CFU-MK colonies were identified as groups of cells possessing blue nuclei and pink membranes. Slides were air dried for 1 h before storing at 4 1C. CFU-MK was quantified within 2 weeks using a light microscope. CFU-MK colonies were subdivided according to size: small (3-20 cells per colony); medium (21-49 cells per colony) or large (450 cells per colony). Mixed colonies were distinguished by the presence of non-Mk cells and megakaryocytes within the same colony.
CFU-MKs were expressed as colonies per millilitre blood. 
Statistical analysis
Analyses were conducted primarily in terms of descriptive summary statistics. Peak CFU-MKs (count per millilitre blood) were analysed using the non-parametric MannWhitney-Wilcoxon test.
Results
Baseline characteristics of the patients are shown in Table 1 . Similar age ranges and tumour types were seen in all groups. A greater proportion of patients in the pegfilgrastim groups had an ECOG performance status X1.
Total colony-forming units
The median total CFU profiles over time (days 1-12) in cycle 0 are shown in Figure 1 and the mean peak CFUs in each treatment group are detailed in Table 2 . There was no meaningful difference among treatment groups with respect to the timing of mobilization with a broad peak seen from days 3 to 7 and the highest median peak falling on day 5 in Table 1 Baseline patient characteristics in pegfilgrastim and filgrastim groups per millilitre respectively; P ¼ 0.024).
Total colony-forming units megakaryocyte
The median total CFU-MK profiles over time (days 1-12) in cycle 0 are shown in Figure 2 and the peak CFU-MK in each treatment group are detailed in Table 2 . The profiles were comparable to the median total CFUs profiles despite the different methodology used to culture these colonies. No clinically meaningful difference was found among the treatment groups with a broad mobilization peak seen from days 3 to 7, the highest median peak falling on day 5 in all groups except for pegfilgrastim 6 mg, in which it fell on day 4. The CFU-MKs profiles demonstrate that fixed doses of pegfilgrastim (12 and 18 mg) are at least as effective as several daily doses of filgrastim (10 mg/kg per day) in mobilizing CFU-MKs. The profiles suggest a positive doseresponse relationship with increasing dose of pegfilgrastim. Only among the patients receiving pegfilgrastim 18 mg was the mean peak number of CFU-MKs significantly higher than in the patients receiving daily filgrastim (1.12 Â 10 4 vs 4.56 Â 10 3 per millilitre respectively; P ¼ 0.024). There was no statistically significant difference between the pegfilgrastim 12 mg and the filgrastim groups (P ¼ 0.563). In the pegfilgrastim 6 mg arm, the mean peak number of CFUMKs was statistically significantly inferior to the patient receiving daily filgrastim (1.42 Â 10 3 vs 4.56 Â 10 3 per millilitre respectively; P ¼ 0.017).
Size of megakaryocyte colonies CFU-MK colonies were subdivided according to size (ploidy): small (3-20 cells per colony); medium (21-49 cells per colony) or large (450 cells per colony). Mixed colonies were distinguished by the presence of non-MK cells and megakaryocytes within the same colony. CFU-MK colony sizes were expressed as a percentage of the total median CFU-MK levels present in the peripheral blood over the 12 days of cycle 0 following treatment with filgrastim 10 mg/kg per day or pegfilgrastim 6 mg, 12 mg and 18 mg (single dose on day 1). In all four treatment arms, the majority of colonies were small at the beginning and the end of the cycle. At the expected peak of megakaryocyte mobilization between days 3 and 7, as well as the total number of CFU-MK increasing, the percentage of medium, large and mixed colonies increased.
Comparison of median CFU-MK progenitor levels detected by IHC and FACS Megakaryocytic progenitors were identified by their CD34/ CD41a co-expression (CD41a monoclonal Ab to GP IIbIIIa). Figures 3a and b are graphs of CD34 only (PBPCs) and CD34/CD41a (PBPC with specific MK differentiation) both detected by FACS analysis, and CFU-MK detected by IHC in the treatment arms pegfilgrastim 18 mg or filgrastim 10 mg/kg per day. Despite Table 2 Peak total colony-forming units ( Â 10 4 per ml blood) and colony-forming units megakaryocyte ( Â 10 4 per ml blood) mobilised into peripheral blood cycle 0 days (3-7)
Filgrastim Pegfilgrastim Abbreviations: CFU ¼ colony-forming unit; CFU-MK ¼ CFU megakaryocyte; N ¼ Number of subjects in the subset analysis. a For subjects with at least three assessments between days 3 and 7. Geometric mean ( Â 10 4 per ml blood). Pegfilgrastim mobilizes megakaryocyte progenitors F Willis et al the different methodology used for the detection of megakaryocytic progenitors, similar profiles and absolute values were seen using the IHC and FACS analysis techniques in both the filgrastim and the pegfilgrastim 18 mg arms. In keeping with the IHC data, the peaks were broad, lasting over days 3-7, with the maximum peak falling on day 5. This suggests that FACS analysis, which is easy to perform and which can be readily automated, could be used as an alternative method for identifying PBPC with megakaryocytic differentiation.
Discussion
Filgrastim, either alone or in combination with chemotherapy, has a well-established role in the mobilization of haemopoietic progenitors into the peripheral blood. [20] [21] [22] Factors influencing the PBPC product include the cytokine used, its dose, whether it is combined with a mobilizing chemotherapy regimen and important patient relatedfactors including age and prior exposure to chemotherapy and radiotherapy. [33] [34] [35] In cycle 0 of this phase I/II study, the use of cytokine alone enabled direct comparison between filgrastim and varying doses of pegfilgrastim as a mobilization agent for megakaryocytic progenitors in the absence of confounding factors in patients with solid tumours. Within this cycle, with both the techniques used (IHC and FACS), in both the filgrastim and the pegfilgrastim groups, the timing of mobilization was consistent with a broad peak seen from days 3 to 7 and the highest median peak falling on day 5 in all groups. This is consistent with the period in which peak values are generally anticipated clinically. There was a positive dose-response relationship with increasing dose of pegfilgrastim and the mean peak CFU-MK count for patients who received pegfilgrastim 18 mg was statistically significantly higher than that seen in the filgrastim group. The correlation between CD41a and CFU-MK based on our data and that of others 17 has shown that CD41a can be used as a surrogate marker. The side effect profiles of pegfilgrastim and filgrastim in this study were very similar.
Megakaryocyte mobilization remains important because thrombocytopenia remains a significant problem in patients receiving non-myeloablative and myeloablative chemotherapy regimens. It is managed primarily by the use of prophylactic platelet transfusions but remains problematic due to their limited supply, short survival, refractoriness and alloimmunization. This has stimulated the search for growth factors, which can reduce or eliminate the need for platelet support.
PBPC transplants using G-CSF (filgrastim and lenograstim) as a mobilizing agent, result in speedier platelet recovery compared to BM and cord transplant patients. 6, 8, 36 This has been shown to be directly related to the CD34 þ and CD41a þ content of the apheresis product. 17, 26 Additionally, no clinically significant neutralizing Ab have been described with G-CSF 37 and it is known to have an excellent safety profile and manageable side effects. 38 Newer mobilizing agents such as AMD3100, a bicyclam compound which inhibits binding of SDF-1 to cognate receptor CXCR4 on CD34 þ stem cells, when combined with G-CSF augments mobilization, but this has not yet been shown to result in speedier platelet recovery. 39, 40 Other cytokines including IL-6 and IL-11 have all been shown to increase platelet counts and accelerate platelet recovery following chemotherapy. However, this is not their primary physiological function, and the pleiotrophic effects of these ILs often results in unwanted and unacceptable side effects including fever, chills, hypotension, dyspnoea and abnormal liver function tests. [41] [42] [43] Thrombopoietin, in addition to G-CSF during mobilization has been shown to increase the CD34 þ and CD34/ CD41a þ yields plus results in small but statistically significant improvements in platelet recovery after transplantation. 12, 15, 44, 45 Clinical trials with thrombopoietin have been hampered, however, due to the development of neutralizing Ab and thrombocytopenia, 46 ,47 risk of thrombocytosis and thrombosis and need for co-administration with G-CSF. 12, 15 This study has shown that pegfilgrastim increases CD34/CD41a þ cells in the peripheral blood, producing similar responses to filgrastim and that it is well tolerated. If this translates into improved yield in the apheresis product and speedier platelet engraftment post transplant, reduced costs in terms of bed days and platelet support will cover the additional cost of the drug.
In summary, administration of pegfilgrastim is safe and well tolerated. It is convenient, once per cycle administration is highly desirable. Pegfilgrastim provides predictable and reliable mobilization with a clear dose-response relationship for all progenitors including CFU-MK. Monitoring of CD34/CD41a by FACS analysis provides a reliable, automated methodology for monitoring megakaryocyte progenitor mobilization. Further randomized trials in PBPC transplant patients are required to establish whether (1) pegfilgrastim, when compared to filgrastim, results in higher CD34 þ /CD41a þ yields in the apheresis product and earlier platelet recovery post transplantation, (2) superior megakaryocyte and progenitor cell mobilization can be achieved by combining pegfilgrastim with other newer mobilizing agents such as the CXCR4 inhibitor AMD3100 or (3) pegfilgrastim can be used in patient groups who mobilize poorly.
